Entry - #613662 - MITOCHONDRIAL DNA DEPLETION SYNDROME 4B (MNGIE TYPE); MTDPS4B - OMIM
# 613662

MITOCHONDRIAL DNA DEPLETION SYNDROME 4B (MNGIE TYPE); MTDPS4B


Alternative titles; symbols

MITOCHONDRIAL NEUROGASTROINTESTINAL ENCEPHALOPATHY SYNDROME, POLG-RELATED
MNGIE, POLG-RELATED


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
15q26.1 Mitochondrial DNA depletion syndrome 4B (MNGIE type) 613662 AR 3 POLG 174763
Clinical Synopsis
 
Phenotypic Series
 

INHERITANCE
- Autosomal recessive
GROWTH
Weight
- Weight loss, progressive
Other
- Thin body habitus
- Marked cachexia
HEAD & NECK
Ears
- Hearing loss (1 patient)
Eyes
- External ophthalmoplegia, progressive (PEO)
ABDOMEN
Liver
- Some patients may have hepatic dysfunction
Gastrointestinal
- Gastrointestinal dysmotility
- Malabsorption
- Chronic malnutrition
- Chronic intestinal pseudoobstruction
- Abdominal pain
- Constipation, chronic
- Abdominal distention
MUSCLE, SOFT TISSUES
- Mitochondrial myopathy
- Hypotonia
- Muscle weakness, diffuse
- Ragged red fibers seen on muscle biopsy
- mtDNA depletion seen on muscle biopsy
- Multiple mitochondrial DNA (mtDNA) deletions seen on muscle biopsy
- Decreased activity of cytochrome c oxidase seen on muscle biopsy
- Decreased activities of complexes I and IV
NEUROLOGIC
Central Nervous System
- Developmental delay (in some)
- Seizures (in some)
- Ataxia
- White matter abnormalities (in some)
Peripheral Nervous System
- Sensory ataxic neuropathy
MISCELLANEOUS
- Onset in infancy or late childhood
- Variable severity
- Some phenotypic overlap with Alpers syndrome (MTDPS4A, 203700)
- Progressive disorder
MOLECULAR BASIS
- Caused by mutation in the DNA polymerase-gamma gene (POLG, 174763.0006)
Mitochondrial DNA depletion syndrome - PS603041 - 25 Entries
Location Phenotype Inheritance Phenotype
mapping key
Phenotype
MIM number
Gene/Locus Gene/Locus
MIM number
1q42.13 Mitochondrial DNA depletion syndrome 21 AR 3 621071 GUK1 139270
2p23.3 Mitochondrial DNA depletion syndrome 6 (hepatocerebral type) AR 3 256810 MPV17 137960
2p13.1 Mitochondrial DNA depletion syndrome 3 (hepatocerebral type) AR 3 251880 DGUOK 601465
2p11.2 Mitochondrial DNA depletion syndrome 9 (encephalomyopathic type with methylmalonic aciduria) AR 3 245400 SUCLG1 611224
3q29 ?Mitochondrial DNA depletion syndrome 14 (encephalocardiomyopathic type) AR 3 616896 OPA1 605290
4q35.1 Mitochondrial DNA depletion syndrome 12A (cardiomyopathic type) AD AD 3 617184 SLC25A4 103220
4q35.1 Mitochondrial DNA depletion syndrome 12B (cardiomyopathic type) AR AR 3 615418 SLC25A4 103220
6q16.1-q16.2 Mitochondrial DNA depletion syndrome 13 (encephalomyopathic type) AR 3 615471 FBXL4 605654
7p22.3 Mitochondrial DNA depletion syndrome 17 AR 3 618567 MRM2 606906
7q34 Sengers syndrome AR 3 212350 AGK 610345
8q22.3 Mitochondrial DNA depletion syndrome 8A (encephalomyopathic type with renal tubulopathy) AR 3 612075 RRM2B 604712
8q22.3 Mitochondrial DNA depletion syndrome 8B (MNGIE type) AR 3 612075 RRM2B 604712
10q21.1 ?Mitochondrial DNA depletion syndrome 15 (hepatocerebral type) AR 3 617156 TFAM 600438
10q24.31 Mitochondrial DNA depletion syndrome 7 (hepatocerebral type) AR 3 271245 TWNK 606075
13q14.2 Mitochondrial DNA depletion syndrome 5 (encephalomyopathic with or without methylmalonic aciduria) AR 3 612073 SUCLA2 603921
14q13.3 ?Mitochondrial DNA depletion syndrome 18 AR 3 618811 SLC25A21 607571
15q26.1 Mitochondrial DNA depletion syndrome 4B (MNGIE type) AR 3 613662 POLG 174763
15q26.1 Mitochondrial DNA depletion syndrome 4A (Alpers type) AR 3 203700 POLG 174763
16q21 Mitochondrial DNA depletion syndrome 2 (myopathic type) AR 3 609560 TK2 188250
17q12 Mitochondrial DNA depletion syndrome 20 (MNGIE type) AR 3 619780 LIG3 600940
17q23.3 ?Mitochondrial DNA depletion syndrome 16B (neuroophthalmic type) AR 3 619425 POLG2 604983
17q23.3 ?Mitochondrial DNA depletion syndrome 16 (hepatic type) AR 3 618528 POLG2 604983
17q25.3 ?Mitochondrial DNA depletion syndrome 19 AR 3 618972 SLC25A10 606794
20p11.23 Mitochondrial DNA depletion syndrome 11 AR 3 615084 MGME1 615076
22q13.33 Mitochondrial DNA depletion syndrome 1 (MNGIE type) AR 3 603041 TYMP 131222

TEXT

A number sign (#) is used with this entry because of evidence that mitochondrial DNA depletion syndrome-4B (MTDPS4B), which manifests as a neurogastrointestinal encephalopathy (MNGIE), is caused by compound heterozygous mutation in the POLG gene (174763) on chromosome 15q26.

See also MTDPS1 (603041) for a more common form of MNGIE caused by recessive mutation in the thymidine phosphorylase gene (TYMP; 131222).


Description

Mitochondrial DNA depletion syndrome-4B (MTDPS4B) is an autosomal recessive progressive multisystem disorder clinically characterized by chronic gastrointestinal dysmotility and pseudoobstruction, cachexia, progressive external ophthalmoplegia (PEO), axonal sensory ataxic neuropathy, and muscle weakness (van Goethem et al., 2003).

For a discussion of genetic heterogeneity of autosomal recessive mtDNA depletion syndromes, see MTDPS1 (603041).


Clinical Features

Vissing et al. (2002) reported 2 sisters who presented at age 15 years with unsteady gait and gastrointestinal malabsorption. Other features included neurogenic changes on EMG, peripheral neuropathy, ophthalmoplegia, and diffuse muscle weakness. The disorder was indistinguishable from that known as mitochondrial gastrointestinal encephalopathy (MNGIE) due to mutation in the TYMP gene (131222), except for absence of leukoencephalopathy on MRI and mildly reduced thymidine phosphorylase activity (42% of control). In addition, no mutation in the TYMP or the DNT2 (605292) gene was found in 1 of the patients. Vissing et al. (2002) suggested that the condition may be due to a nuclear gene mutation causing a defect in intergenomic signaling.

Van Goethem et al. (2003) provided a follow-up of the patients reported by Vissing et al. (2002). Features included chronic gastrointestinal pseudoobstruction, PEO, axonal sensory ataxic neuropathy, muscle weakness, and cachexia. Brain MRI was normal. Muscle biopsy demonstrated few ragged-red fibers, cytochrome c oxidase negative fibers, decreased enzymatic activities of respiratory chain complexes I and IV, depletion of mtDNA, and multiple mtDNA deletions.

Giordano et al. (2009) reported a newborn boy with congenital myopathy and gastrointestinal pseudoobstruction due to compound heterozygous mutations in the POLG gene (174763.0006 and 174763.0021). He presented with severe hypotonia and generalized muscle weakness, requiring ventilatory assistance and total parenteral nutrition. Hearing loss was detected by auditory evoked potentials, and brain MRI showed mildly enlarged ventricles, but leukoencephalopathy was not noted. He also developed severe abdominal distention with a hypoactive bowel. MRI revealed marked intestinal dilation without mechanical obstruction. Other features included low-set ears, hearing loss, and bilateral clubfoot. Laboratory studies showed hypoglycemia, hypomagnesemia, and hypokalemia; lactate was normal, and liver enzymes were unremarkable. Skeletal muscle biopsy showed scattered, hypertrophic COX-deficient fibers, and there was marked mtDNA depletion in muscle (93% decrease compared to controls). The patient died at age 20 days from respiratory failure. There was no liver damage aside from that resulting from parenteral nutrition. Analysis of the bowel showed that mtDNA depletion was confined mainly to the external layer of the muscularis propria.

Kurt et al. (2010) reported 2 unrelated patients, a girl and a boy, with mtDNA depletion associated with features of MNGIE and of Alpers syndrome with hepatic involvement (MTDPS4A; 203700). Both had compound heterozygous mutations in the POLG gene (P1073L (174763.0022) in both, and A467T (174763.0002) and G848S (174763.0006), respectively). Both patients showed developmental delay. The girl was hypotonic at birth, and later had short stature, neurosensory hearing loss, celiac disease, liver dysfunction with hepatic fibrosis, and gastrointestinal pseudoobstruction with dysmotility. Brain MRI showed signal abnormalities in the basal ganglia and thalami. She died at age 9 years. RT-PCR showed severe mtDNA depletion in liver tissue (72.1% depletion compared to controls). The boy had poor growth, hypotonia, seizures, and intestinal hypomotility, and died at age 10 months. Muscle tissue showed mtDNA depletion (64%). Kurt et al. (2010) emphasized the phenotypic variability associated with recessive POLG mutations, and noted that various signs and symptoms can occur.


Molecular Genetics

In 2 sisters with features of MNGIE but no leukoencephalopathy in whom no mutations were found in the TYMP gene by Vissing et al. (2002), Van Goethem et al. (2003) identified compound heterozygosity for 3 mutations in the POLG gene: T251I (174763.0007) and P587L (174763.0011), which were in cis on the same allele, and N864S (174763.0012), which was in trans.

In a male infant with mtDNA depletion syndrome-4B manifest as severe hypotonia and gastrointestinal dysmotility (MNGIE), Giordano et al. (2009) identified compound heterozygosity for 2 mutations in the POLG gene: G848S (174763.0006) and R227W (174763.0021).


REFERENCES

  1. Giordano, C., Powell, H., Leopizzi, M., De Curtis, M., Travaglini, C., Sebastiani, M., Gallo, P., Taylor, R. W., d'Amati, G. Fatal congenital myopathy and gastrointestinal pseudo-obstruction due to POLG1 mutations. Neurology 72: 1103-1105, 2009. Note: Erratum: Neurology 73: 738 only, 2009. [PubMed: 19307547, related citations] [Full Text]

  2. Kurt, B., Jaeken, J., Van Hove, J., Lagae, L., Lofgren, A., Everman, D. B., Jayakar, P., Naini, A., Wierenga, K. J., Van Goethem, G., Copeland, W. C., DiMauro, S. A novel POLG gene mutation in 4 children with Alpers-like hepatocerebral syndromes. Arch. Neurol. 67: 239-244, 2010. [PubMed: 20142534, images, related citations] [Full Text]

  3. Van Goethem, G., Schwartz, M., Lofgren, A., Dermaut, B., Van Broeckhoven, C., Vissing, J. Novel POLG mutations in progressive external ophthalmoplegia mimicking mitochondrial neurogastrointestinal encephalomyopathy. Europ. J. Hum. Genet. 11: 547-549, 2003. [PubMed: 12825077, related citations] [Full Text]

  4. Vissing, J., Ravn, K., Danielsen, E. R., Duno, M., Wibrand, F., Wevers, R. A., Schwartz, M. Multiple mtDNA deletions with features of MNGIE. Neurology 59: 926-929, 2002. [PubMed: 12297582, related citations] [Full Text]


Creation Date:
Cassandra L. Kniffin : 12/6/2010
carol : 12/02/2024
carol : 03/15/2022
carol : 06/08/2016
carol : 12/21/2010
ckniffin : 12/10/2010

# 613662

MITOCHONDRIAL DNA DEPLETION SYNDROME 4B (MNGIE TYPE); MTDPS4B


Alternative titles; symbols

MITOCHONDRIAL NEUROGASTROINTESTINAL ENCEPHALOPATHY SYNDROME, POLG-RELATED
MNGIE, POLG-RELATED


ORPHA: 298;   DO: 0080123;  


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
15q26.1 Mitochondrial DNA depletion syndrome 4B (MNGIE type) 613662 Autosomal recessive 3 POLG 174763

TEXT

A number sign (#) is used with this entry because of evidence that mitochondrial DNA depletion syndrome-4B (MTDPS4B), which manifests as a neurogastrointestinal encephalopathy (MNGIE), is caused by compound heterozygous mutation in the POLG gene (174763) on chromosome 15q26.

See also MTDPS1 (603041) for a more common form of MNGIE caused by recessive mutation in the thymidine phosphorylase gene (TYMP; 131222).


Description

Mitochondrial DNA depletion syndrome-4B (MTDPS4B) is an autosomal recessive progressive multisystem disorder clinically characterized by chronic gastrointestinal dysmotility and pseudoobstruction, cachexia, progressive external ophthalmoplegia (PEO), axonal sensory ataxic neuropathy, and muscle weakness (van Goethem et al., 2003).

For a discussion of genetic heterogeneity of autosomal recessive mtDNA depletion syndromes, see MTDPS1 (603041).


Clinical Features

Vissing et al. (2002) reported 2 sisters who presented at age 15 years with unsteady gait and gastrointestinal malabsorption. Other features included neurogenic changes on EMG, peripheral neuropathy, ophthalmoplegia, and diffuse muscle weakness. The disorder was indistinguishable from that known as mitochondrial gastrointestinal encephalopathy (MNGIE) due to mutation in the TYMP gene (131222), except for absence of leukoencephalopathy on MRI and mildly reduced thymidine phosphorylase activity (42% of control). In addition, no mutation in the TYMP or the DNT2 (605292) gene was found in 1 of the patients. Vissing et al. (2002) suggested that the condition may be due to a nuclear gene mutation causing a defect in intergenomic signaling.

Van Goethem et al. (2003) provided a follow-up of the patients reported by Vissing et al. (2002). Features included chronic gastrointestinal pseudoobstruction, PEO, axonal sensory ataxic neuropathy, muscle weakness, and cachexia. Brain MRI was normal. Muscle biopsy demonstrated few ragged-red fibers, cytochrome c oxidase negative fibers, decreased enzymatic activities of respiratory chain complexes I and IV, depletion of mtDNA, and multiple mtDNA deletions.

Giordano et al. (2009) reported a newborn boy with congenital myopathy and gastrointestinal pseudoobstruction due to compound heterozygous mutations in the POLG gene (174763.0006 and 174763.0021). He presented with severe hypotonia and generalized muscle weakness, requiring ventilatory assistance and total parenteral nutrition. Hearing loss was detected by auditory evoked potentials, and brain MRI showed mildly enlarged ventricles, but leukoencephalopathy was not noted. He also developed severe abdominal distention with a hypoactive bowel. MRI revealed marked intestinal dilation without mechanical obstruction. Other features included low-set ears, hearing loss, and bilateral clubfoot. Laboratory studies showed hypoglycemia, hypomagnesemia, and hypokalemia; lactate was normal, and liver enzymes were unremarkable. Skeletal muscle biopsy showed scattered, hypertrophic COX-deficient fibers, and there was marked mtDNA depletion in muscle (93% decrease compared to controls). The patient died at age 20 days from respiratory failure. There was no liver damage aside from that resulting from parenteral nutrition. Analysis of the bowel showed that mtDNA depletion was confined mainly to the external layer of the muscularis propria.

Kurt et al. (2010) reported 2 unrelated patients, a girl and a boy, with mtDNA depletion associated with features of MNGIE and of Alpers syndrome with hepatic involvement (MTDPS4A; 203700). Both had compound heterozygous mutations in the POLG gene (P1073L (174763.0022) in both, and A467T (174763.0002) and G848S (174763.0006), respectively). Both patients showed developmental delay. The girl was hypotonic at birth, and later had short stature, neurosensory hearing loss, celiac disease, liver dysfunction with hepatic fibrosis, and gastrointestinal pseudoobstruction with dysmotility. Brain MRI showed signal abnormalities in the basal ganglia and thalami. She died at age 9 years. RT-PCR showed severe mtDNA depletion in liver tissue (72.1% depletion compared to controls). The boy had poor growth, hypotonia, seizures, and intestinal hypomotility, and died at age 10 months. Muscle tissue showed mtDNA depletion (64%). Kurt et al. (2010) emphasized the phenotypic variability associated with recessive POLG mutations, and noted that various signs and symptoms can occur.


Molecular Genetics

In 2 sisters with features of MNGIE but no leukoencephalopathy in whom no mutations were found in the TYMP gene by Vissing et al. (2002), Van Goethem et al. (2003) identified compound heterozygosity for 3 mutations in the POLG gene: T251I (174763.0007) and P587L (174763.0011), which were in cis on the same allele, and N864S (174763.0012), which was in trans.

In a male infant with mtDNA depletion syndrome-4B manifest as severe hypotonia and gastrointestinal dysmotility (MNGIE), Giordano et al. (2009) identified compound heterozygosity for 2 mutations in the POLG gene: G848S (174763.0006) and R227W (174763.0021).


REFERENCES

  1. Giordano, C., Powell, H., Leopizzi, M., De Curtis, M., Travaglini, C., Sebastiani, M., Gallo, P., Taylor, R. W., d'Amati, G. Fatal congenital myopathy and gastrointestinal pseudo-obstruction due to POLG1 mutations. Neurology 72: 1103-1105, 2009. Note: Erratum: Neurology 73: 738 only, 2009. [PubMed: 19307547] [Full Text: https://doi.org/10.1212/01.wnl.0000345002.47396.e1]

  2. Kurt, B., Jaeken, J., Van Hove, J., Lagae, L., Lofgren, A., Everman, D. B., Jayakar, P., Naini, A., Wierenga, K. J., Van Goethem, G., Copeland, W. C., DiMauro, S. A novel POLG gene mutation in 4 children with Alpers-like hepatocerebral syndromes. Arch. Neurol. 67: 239-244, 2010. [PubMed: 20142534] [Full Text: https://doi.org/10.1001/archneurol.2009.332]

  3. Van Goethem, G., Schwartz, M., Lofgren, A., Dermaut, B., Van Broeckhoven, C., Vissing, J. Novel POLG mutations in progressive external ophthalmoplegia mimicking mitochondrial neurogastrointestinal encephalomyopathy. Europ. J. Hum. Genet. 11: 547-549, 2003. [PubMed: 12825077] [Full Text: https://doi.org/10.1038/sj.ejhg.5201002]

  4. Vissing, J., Ravn, K., Danielsen, E. R., Duno, M., Wibrand, F., Wevers, R. A., Schwartz, M. Multiple mtDNA deletions with features of MNGIE. Neurology 59: 926-929, 2002. [PubMed: 12297582] [Full Text: https://doi.org/10.1212/wnl.59.6.926]


Creation Date:
Cassandra L. Kniffin : 12/6/2010

Edit History:
carol : 12/02/2024
carol : 03/15/2022
carol : 06/08/2016
carol : 12/21/2010
ckniffin : 12/10/2010